SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pluristem Therapeutics
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
295 17 0 PSTI
Emcee:  FJB Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
120Pluristem Therapeutics Approved for Dual Listing on the Tel Aviv Stock Exchange xcentral1-12/13/2010
119from the Overview section of the 10K Overview We are a bio-therapeutics compaxcentral1-11/11/2010
118Six Reasons to Like Pluristem Therapeutics I am recommending that readers take xcentral1-10/14/2010
117Corporate Profile's CPReports.com Publishes RAY DIRKS Research's Report xcentral1-10/13/2010
116BRIEF: Pluristem raises $5.25m from institutional, private investors Oct 12, 2xcentral1-10/13/2010
115Data from Clinical Trials Show Pluristem's Placenta-Derived Cell Therapy is xcentral1-9/14/2010
114Pluristem's Placenta Derived Cells Chosen by European Commission's Sevenxcentral1-8/30/2010
113Pluristem's PLX Cells Found to Be Effective in Treating Neuropathic and Inflxcentral1-8/9/2010
112Pluristem Appoints Diabetic Neuropathy and Vascular Disease Expert, Dr. Aristidixcentral1-8/4/2010
111 Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Crxcentral1-7/1/2010
110Pluristem's Off-The-Shelf Placenta-Derived Cell Therapies - The Focus of Prexcentral1-5/20/2010
109Here's fabulous Video from ABC 11.. PSTI and Duke U and Berger's Diseaxcentral1-5/10/2010
108Pluristem Therapeutics' Dr. William Prather Interviewed on CorporateProfile.xcentral1-5/5/2010
107HAIFA, ISRAEL, April 29, 2010--Pluristem Therapeutics Inc. today announced that xcentral1-4/29/2010
106Pluristem Therapeutics Announces Interim Top-Line Results From PLX--PAD Clinicalxcentral1-4/27/2010
105Pluristem Therapeutics Raises $2.7 Million in Private Placement of Restricted Coxcentral1-4/27/2010
104Pluristem Therapeutics Granted European Union Patent for PluriX™ Three-Dimensionxcentral1-3/23/2010
103Pluristem to Present at the ROTH 22nd Annual OC Growth Conference HAIFA, Israexcentral1-3/9/2010
102Tic-tock... tic-tock... Pluristem Therapeutics Receives DSMB Approval to Advancxcentral1-3/5/2010
101Pluristem's PLX Cells May Effectively Treat Ischemic Stroke - Brain Researchxcentral1-2/3/2010
100Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials Dxcentral1-1/11/2010
99Data Safety Monitoring Board (DSMB) Approves Advancement to Intermediate Dose Lexcentral1-12/15/2009
98Pluristem Will Present on the Value of Placental-derived Mesenchymal Stromal Celxcentral1-12/10/2009
97The talent of the Board of Directors: Principal Employment and Experience of Dixcentral1-12/8/2009
96Obama to OK embryonic stem cell research Plans reversal of Bush policy as alternxcentral1-12/2/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News